This week on “The Top Line,” we’re speaking with Jared Baeten, MD, Ph.D., Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment research have enabled individuals to lead longer and healthier lives by taking and staying on medication. Nevertheless, HIV persists as a significant public health challenge. To end the HIV epidemic, it is crucial to go beyond a biomedical approach and fully integrate social determinants of health into the collective response. Not everyone is achieving long-term success.
Long-term success involves meeting more than the United Nations’ goals of ending the epidemic by 2030. Treatment selection can help prioritize long-term outcomes from the very beginning. There are several other key factors for people with HIV and their healthcare providers to consider when assessing treatment choices, such as the resistance and safety profile of a treatment, drug-to-drug interaction potential, and comorbid conditions.
This podcast is brought to you by Gilead Sciences. Visit gileadhivtogether.com to learn more about Gilead’s unique collaborations worldwide and the work to help end the HIV epidemic.
See omnystudio.com/listener for privacy information.
May 5, 2023
April 27, 2023
April 21, 2023
April 14, 2023
April 7, 2023
March 31, 2023
March 24, 2023
[Sponsored] Is your biotech ready for 2023? MacDougall Advisors has insight
March 17, 2023
March 10, 2023
March 3, 2023
February 24, 2023
February 17, 2023
[Sponsored] New Era in Biologically Targeted Radiotherapy to Combat Cancer
February 10, 2023
February 3, 2023
January 27, 2023
January 20, 2023
January 13, 2022
January 6, 2022
Create your
podcast in
minutes
It is Free
Pharmacy Podcast Network
Børsen Morgenbriefing
Sarah Westall - Business Game Changers
Startitup podcasty
Wall Street Breakfast